Orchestra BioMed Announces Proposed Public Offering

Planned proceeds would support the AVIM Therapy and Virtue SAB programs, including their clinical trials.

Rhea-AI Summary

Orchestra BioMed (Nasdaq: OBIO) has commenced an underwritten public offering of common stock, with all shares offered by the company. It intends to grant underwriters a 30-day option to buy up to an additional 15% of the shares sold, at the public offering price less underwriting discounts and commissions.

The company plans to use net proceeds together with existing cash to fund its AVIM Therapy program and BACKBEAT pivotal trial, its Virtue SAB program and Virtue Trial, and other research and clinical development, with the remainder for working capital and general corporate purposes. Completion and terms remain subject to market and other conditions.

4 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed common-stock offering would raise funding for Orchestra BioMed.
• Minor point. Forward-looking: it has not happened yet and may not happen.Planned proceeds use includes the AVIM Therapy program and BACKBEAT global pivotal trial.
• Minor point. Forward-looking: it has not happened yet and may not happen.Planned proceeds use includes the Virtue SAB program and Virtue Trial.
• Minor point. Forward-looking: it has not happened yet and may not happen.Other product candidates would receive funding for research and clinical development.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.New common shares would dilute existing holders if the offering is completed.
• Minor point. Forward-looking: it has not happened yet and may not happen.Proposed 30-day underwriter option covers up to an additional 15% of shares sold, adding potential dilution.
• Minor pointOffering completion and terms remain subject to market and other conditions.

News Explained

The company has commenced the offering; if completed, it would issue new common shares and receive proceeds, increasing the share count and reducing existing holders’ percentage ownership, but its undisclosed size and price mean dilution cannot yet be sized.

Argus 15 min delay 14 alerts

-11.92% vs previous close $4.95 last price 1.0x rel. volume Open Argus

Details

Market Reaction – OBIO

$4.65 – $6.14 Day Range

$297.52M Mkt Cap at Last Price

On Nov 5, the day this news came out, the latest delayed price for OBIO is 11.92% below the previous close. Our momentum scanner has recorded 14 alerts for this stock so far that day. The latest delayed price is $4.95.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Underwriter option: 30 days; up to 15% of shares sold

Underwriter option

30 days; up to 15% of shares sold

Proposed additional common shares at the public offering price, less underwriting discounts and commissions

Previous Offering Reports

2 past events · Latest: Jul 31

Same Type 2 events

1. Jul 31

   Proposed public offering

   24h Move

   -20.3%

   Proposed common-stock offering included the same 30-day option for up to 15% additional shares.

2. Aug 01

   Public offering priced

   24h Move

   -20.3%

   The company priced a $40 million offering of shares and pre-funded warrants at disclosed per-unit prices.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, shelf registration statement, form s-3, in-stent restenosis

4 terms

underwritten public offering financial

"commenced an underwritten public offering of shares of its common stock"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"offered pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"a shelf registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

in-stent restenosis medical

"Virtue SAB in the Treatment of Coronary In-Stent Restenosis Trial"

In-stent restenosis is the re-narrowing of an artery at the site where a metal or drug-coated tube (stent) was placed to keep it open, caused by scar tissue or cell growth inside the stent. For investors, it matters because it drives demand for follow-up treatments, influences the perceived effectiveness and safety of stent products, and can affect regulatory scrutiny, reimbursement and long-term sales for companies that make stents or therapies to prevent or treat re-narrowing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, announced today that it has commenced an underwritten public offering of shares of its common stock (the “Offering”). All of the securities are being offered by the Company. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of its common stock sold in the Offering at the public offering price per share, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

The Company intends to use the net proceeds it receives from the Offering, together with its existing cash and cash equivalents, to fund the Company’s Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) program and the execution of the BACKBEAT global pivotal trial involving patients with uncontrolled hypertension who are indicated for a dual-chamber pacemaker (the “Backbeat Trial”) and to fund its Virtue® Sirolimus AngioInfusion Balloon (“Virtue SAB”) program and the Virtue SAB in the Treatment of Coronary In-Stent Restenosis Trial (the “Virtue Trial”), as well as research and clinical development of other current or additional product candidates, and the remainder for working capital and other general corporate purposes.

Piper Sandler and TD Cowen are acting as joint bookrunning managers for the Offering. BTIG is acting as a bookrunner.

The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-279430) that was filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2024 and declared effective on May 24, 2024. The Offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement related to and describing the terms of the Offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and an accompanying prospectus related to the Offering may also be obtained, when available, from: Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, or by telephone at (800) 747-3924, or by email at prospectus@psc.com; or TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at TDManualrequest@broadridge.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - AVIM Therapy and Virtue SAB - are currently undergoing pivotal clinical trials for their lead indications.

AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic (NYSE: MDT), one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has two FDA Breakthrough Device Designations. The BACKBEAT Trial evaluating AVIM Therapy in this population has completed enrollment.

Virtue SAB is a first-of-its-kind, non-coated drug delivery AngioInfusion™ balloon system designed to infuse a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB exceeded the published pharmacokinetics of leading limus drug-eluting stents and demonstrated positive three-year clinical data in coronary In-Stent Restenosis in the SABRE study, a multi-center prospective, independent core lab-adjudicated pilot clinical study of 50 patients conducted in Europe. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease, in each case, within specified parameters. The Virtue Trial is currently enrolling patients.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the proposed Offering, including the completion and timing of the Offering, the anticipated use of proceeds from the Offering and the expectation to grant the underwriters a 30-day option to purchase additional shares . These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s commercial product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 12, 2026, as such discussion may be updated from time to time by subsequent filings the Company may make with the SEC, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the Offering.

The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

Investor Contact
Silas Newcomb
Orchestra BioMed
snewcomb@orchestrabiomed.com

Media Contact
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Orchestra BioMed proposing in its OBIO public offering?

Orchestra BioMed has commenced an underwritten public offering of common stock, with all securities offered by the company. It intends to give underwriters a 30-day option to purchase up to an additional 15% of the shares sold at the public offering price, less underwriting discounts and commissions.

How does Orchestra BioMed plan to use the offering proceeds?

Orchestra BioMed plans to combine net offering proceeds with existing cash and cash equivalents to fund its AVIM Therapy and Virtue SAB programs and their trials. Funding would also support research and clinical development of other current or additional product candidates, with the remainder for working capital and general corporate purposes.